End of Summer Biotech Reading List

How Two Common Medications Became One $455 Million Specialty Pill
Marshall Allen (The Atlantic)
 
The Startling History Behind Merck's New Cancer Blockbuster
David Shaywitz (Forbes)
 
Conquering HIV’s capsid: After a dozen years, researchers have struck upon a molecule that can disrupt an elusive HIV target
Lisa Jarvis (Chemistry & Engineering News)
 
Birth of CRISPR’d pigs advances hopes for turning swine into organ donors
Sharon Begley (STAT News)
 
Opinionome: The past and future value of GWAS
Tom Ulrich (Broad Institute)
 
What’s Harder Than Making Copycat Biotech Drugs? Selling Them
Jared Hopkins (Bloomberg)
 
Did the CEO Actually Get Fired? There’s a Decoder for That
Vanessa Fuhrmans (Wall Street Journal)